Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. betascreen

BETASCREEN

A Unique Pancreatic Human Beta Cells to revolutionize the Diabetes Drug Discovery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BETASCREEN project word cloud

Explore the words cloud of the BETASCREEN project. It provides you a very rough idea of what is the project "BETASCREEN" about.

disruptive    biosolutions    15    portfolio    poor    issue    world    pharmaceutical    substitute    commercial    dollars    generation    exceptional    predictive    technologies    patients    edge    maturity    industrial    adoption    ub    rentability    110    samples    says    ultimate    saving    hope    quantity    academia    leaders    solution    tornell    90    europe    creation    overcome    million    cell    revenues    pressure    screening    marketed    astrazeneca    think    replication    betascreen    jobs    biotech    population    accessible    cutting    drug    1billion    tissues    faced    commercialization    surprise    diabetes    models    turnover    attrition    jan    line    ing    prevents    human    stem    anti    division    innovative    industry    rate    decreasing    big    predictability    pharma    secure    accelerate    scarce    strategy    10    pharmas    clinical    animal    cells    generating    2021    lines    reproducibility    regulatory    pancreatic    beta    coherence    avenues    leader    market    univercell    selling    strategic    pioneering    company    first    types    homogeneity    industrials    lack    2015    outcome    segments    bottlenecks   

Project "BETASCREEN" data sheet

The following table provides information about the project.

Coordinator		 UNIVERCELL BIOSOLUTIONS SAS 

Organization address
address: PLACE PIERRE POTIER CENTRE PIERRE POTIER CANCEROPOLE ENTREE B
city: TOULOUSE
postcode: 31000
website: www.univercell-biosolutions.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website http://www.endocells.com/products-and-services/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2017-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERCELL BIOSOLUTIONS SAS FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

Univercell Biosolutions (UB) is a pioneering biotech company providing unique human cell models to accelerate and secure pharmaceutical products. UB is generating 1 M€ turnover in 2015 selling its first generation of human beta cell lines to 10 world pharma industry leaders. Pharmas rentability is decreasing facing to high regulatory pressure and low clinical predictability on human. The rate of clinical drug failure is about 90% and cost for marketed a new drug reach up to 1billion dollars. Early clinical predictability is a strategic issue for industrials. Jan Tornell an AstraZeneca division leader says: “The big think is that when we get into patients, we want no surprise”. Cells from human tissues samples are scarce and not accessible for Pharmas applications. Thus, Industrials developed substitute from animal with poor clinical predictability. Recently, Stem cell technologies has open new hope in providing large quantity of human cells but is still faced with major bottlenecks: lack of cell maturity (clinical predictability) and low cell population homogeneity (reproducibility) which prevents large adoption by industrials. UB has developed a portfolio of cutting edge technologies to overcome these bottlenecks. The first outcome of BETASCREEN is a disruptive pancreatic beta cell line for anti-diabetes research, with ultimate objective of replication to other cell types. The solution targets pharmaceutical, biotech, and academia. Within BETASCREEN, UB will define best commercialization strategy in coherence with market’s targeted segments and identify industrial partners for large-scale production (Phase 2) and commercialization. BETASCREEN will improve the predictive value of screening by decreasing the drug attrition rate up to 10%. Resulting cost saving for industrials could reach 100 million dollars per innovative new drug development. This will open exceptional commercial avenues for UB with revenues estimated at 15 M€ in 2021 and 110 jobs creation in Europe

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETASCREEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETASCREEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More